Search results for: methotrexate

Diet, Microbes & Inflammation: Unique Microbial Genetic Strains in Inflammatory Disease, Plus a Possible Arthritis Diet

Susan Bernstein | March 4, 2021

Experts at ACR Convergence 2020 addressed how diet & the body’s microbiome affect chronic diseases.

The Character of Rheumatology Has Changed Over the Past 50 Years

Bruce Rothschild, MD | February 16, 2021

Camelot allegedly existed once upon a time in South Wales. The name was evoked again in the 1960s, but perhaps it is also applicable to the character of rheumatology in the halcyon days of the 1970s and 80s. That’s not to belittle the world we now live in, with so many treatment options for our…

Research Outlines Benefits of bDMARDs to Treat Early RA

Michele B. Kaufman, PharmD, BCGP | February 10, 2021

Sapart et al. suggest a combination of methotrexate and biologic disease-modifying anti-rheumatic drugs as induction therapy for patients with early RA may lead to long-term remission.

Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More

Michele B. Kaufman, PharmD, BCGP | February 8, 2021

In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP | February 4, 2021

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.

Diagnostic Drill-Down: New Research Suggests Genetic Autoinflammatory Roots

Mary Beth Nierengarten | January 25, 2021

Two experts discussed ongoing difficulties in diagnosing autoinflammatory disease, & promising new studies that point to possible genetic roots of autoinflammatory disease.

The State of Clinical Research in Vasculitis: 2021

Shubhasree Banerjee, MD, & Peter A. Merkel, MD, MPH | January 19, 2021

It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

The 2020 ACR Review Course: Key Issues Rheumatologists Face

Jason Liebowitz, MD, FACR | December 17, 2020

The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.

The Case for Integrated Musculoskeletal Care Teams

Samantha C. Shapiro, MD, with Karl Koenig, MD | December 14, 2020

Through the development of a multidisciplinary musculoskeletal institute, we have created a model that facilitates coordination of care of complex patients between medical and surgical subspecialists, physical therapists, dieticians and social workers. A case is presented to demonstrate the improved care experience for both patients and providers and to share our learnings more broadly. The…

Biologics in Rheumatology: Revolution & Perspectives

Lara C. Pullen, PhD | December 8, 2020

A great deal of progress has been made in the treatment of rheumatic diseases—from glucocorticoid use to the advent of biologic therapies. Gerd Burmester, MD, discussed this progress and the impact of biologics in this year’s Phillip Hench, MD, Memorial Lecture.